Buy (150 RUB)
|Generate QR code
Open Access
Subscription or Fee Access
The use of sweeteners and sugar substitutes in the food industry. Sweet proteins as a new alternative
I. V. Maev,
A. V. Zaborovsky,
S. V. Tsaregorodtsev,
D. V. Yunina,
Yu. A. Kolosov,
M. Yu. Starovoytova,
L. A. Tararina https://doi.org/10.33667/2078-5631-2024-16-58-64
Abstract
This review examines the consequences of excessive consumption of sweet products on human health and explores the potential of sugar substitutes and intensive sweeteners, including sweet proteins, as their healthier alternatives. Analyzing statistical data on the prevalence of diabetes and obesity, the study highlights the health risks associated with high sugar intake. An extensive review of the properties of various sugar substitutes and sweeteners has been conducted, focusing on their glycemic index and sweetness level. Special attention is given to sweet proteins, such as monellin and brazzein, their structure, and biological effects. Sweet proteins have a significantly high sweetness index and can serve as an alternative to traditional sugar in food production. However, their application in the food or pharmaceutical industry is limited. The study emphasizes the potential of sugar substitutes and sweeteners, especially sweet proteins, in developing food products by reducing sugar content. Nonetheless, further research is required to ensure the safety of sweet proteins and understand their long-term effects on human health.
About the Authors
I. V. Maev
Federal State Budgetary Educational Institution of Higher Education “Russian University of Medicine” of Ministry of Health of Russia
Russian Federation
Russian Federation
Maev Igor V., DM Sci (habil.), academician of the Russian Academy of Sciences, head of Dept of Propaedeutics of Internal Diseases and Gastroenterology at Scientific and Educational Institute of Clinical Medicine named after N. A. Semashko
Moscow
A. V. Zaborovsky
Federal State Budgetary Educational Institution of Higher Education “Russian University of Medicine” of Ministry of Health of Russia
Russian Federation
Russian Federation
Zaborovskiy Andrey V., DM Sci (habil.), associate professor, head of Dept of Pharmacology at Scientific and Educational Institute of Clinical Medicine named after N. A. Semashko
Moscow
S. V. Tsaregorodtsev
Federal State Budgetary Educational Institution of Higher Education “Russian University of Medicine” of Ministry of Health of Russia
Russian Federation
Russian Federation
Tsaregorodtsev Sergei V., lecturer at Dept of Pharmacology at Scientific and Educational Institute of Clinical Medicine named after N. A. Semashko
Moscow
D. V. Yunina
Federal State Budgetary Educational Institution of Higher Education “Russian University of Medicine” of Ministry of Health of Russia
Russian Federation
Russian Federation
Yunina Dina V., lecturer at Dept of Pharmacology at Scientific and Educational Institute of Clinical Medicine named after N. A. Semashko
Moscow
Yu. A. Kolosov
Federal State Budgetary Educational Institution of Higher Education “Russian University of Medicine” of Ministry of Health of Russia
Russian Federation
Russian Federation
Kolosov Yuri A., PhD Med, associate professor, deputy director for Educational Affairs of K. M. Lakin Scientific and Educational Institute of Pharmacy
Moscow
M. Yu. Starovoytova
Federal State Budgetary Educational Institution of Higher Education “Russian University of Medicine” of Ministry of Health of Russia
Russian Federation
Russian Federation
Starovoytova Maria Y., student at Faculty of Medicine.
Moscow
L. A. Tararina
Federal State Budgetary Educational Institution of Higher Education “Russian University of Medicine” of Ministry of Health of Russia
Russian Federation
Russian Federation
Tararina Larisa A., senior lecturer at Dept of Pharmacology at Scientific and Educational Institute of Clinical Medicine named after N. A. Semashko
Moscow
References
1. Dedov I. I., Shestakova M. V., Vikulova O. K. et al. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes mellitus. 2021; 24 (3): 204–221. (In Russ.). https:.doi.org/10.14341/DM12759
2. Xiaoda S., Yuting Y., Li L. et al. Design and development of a high temperature stable sweet protein base on monellin. Process Biochemistry. 2020; 89: 29–36.
3. Kayode R. M.O., Abiodun O. A., Akeem S. A., Oyeneye H. O. Influence of partial substitution of sugar with serendipity berry (dioscoreophyllum cumminsii) extract on the quality attributes and shelf-life of wheat bread. J. Microbiol Biotech Food Sci / Kayode et al. 2019; 9(1): 115–120.
4. Spadaccini R., Crescenzi O., Tancredi T. et al. Solution structure of a sweet protein: NMR study of MNEI, a single chain monellin. Journal of Molecular Biology. 2001; 305: 505–514.
5. Ming D., Hellekant G. Brazzein, a new high-potency thermostable sweet protein from Pentadiplandra brazzeana B. FEBS Lett. 1994; 355(1):106–8. DOI: 10.1016/0014–5793(94)01184–2
6. Izawa H., Ota M., Kohmura M., Ariyoshi Y. Synthesis and characterization of the sweet protein brazzein. Biopolymers. 1996; 39 (1): 95–101. DOI: 10.1002/(SICI)1097–0282(199607)39:1<95: AID-BIP10>3.0.CO;2-B
7. Pfeiffer J. F., Boulton R. B., Noble A. C. Modelling the sweetness response using time-intensity data. Food Quality & Preference. 2000; 11: 129–134.
8. Hellekant G., Danilova V. Brazzein a Small, Sweet Protein: Discovery and Physiological Overview. Chem. Senses. 2005; 30 (suppl 1): i88–i89. DOI: 10.1093/chemse/bjh127
9. Ming D., Markley J. L., Hellekant G. Quantification of Cysteinyl Sulfhydryl Residues in Peptides and Proteins by ESIMS or MALDIMS. BioTechniques. 1995; 18 (5): 808–10.
10. Jin Z., Danilova V., Assadi-Porter F.M. et al. Critical regions for the sweetness of brazzein. FEBS Lett. 2003. https: doi.org/10.1016/S 0014–5793(03)00383–1
11. Assadi-Porter F.M., Aceti D. J., Cheng H., Markley J. L. Efficient production of recombinant brazzein, a small, heat-stable, sweet-tasting protein of plant origin. Arch. Biochem. Biophys. 2000, 376 (2): 252-–258. DOI: 10.1006/abbi.2000.1725
12. Kinnamon S. C. Taste receptor signaling- from tongues to lungs. Acta Physiol (Oxf). 2012; 204 (2): 158–68.
13. Cui M., Jiang P., Maillet E. et al. The heterodimeric sweet tase receptor has multiple potential ligand binding sites. Curr Pharm Des. 2006; 12 (35): 4591–600.
14. Lazutkaite G., Solda A., Lossow K. et al. Amina acid sensing in hypothalamic tanycytes via umami taste receptors. Mol. Metab. 2017; 6(11):1480–1492. DOI: 10.1016/j.molmet.2017.08.015
15. Chen A. N.Y., Hellyer S. D., Trinh P. N.H. et al. Identification of monellin as the first naturally-derived proteinaceous allosteric agonist of metabotropic glutamate receptor 5. Basic Clin Pharmacol Toxicol. 2020; 126(6):104–115. DOI: 10.1111/bcpt.13239
16. Cancellere R. Metabolic effects of the sweet protein MNEI as a sweetener in drinking water. A pilot study of a high fat dietary regimen in a rodent model. Nutrients. 2019; 11(11): 2643.
17. Chung J. H., Kong J. N., Choi H. E., Kong K. H. Antioxidant, anti-inflammatory, and anti-allergic activities of the sweet-tasting protein brazzein. Food Chemistry. 2018; 267: 163–169.
18. Suez J., Korem T., Zeevi D. et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature. 2014; 514:181–186. DOI: 10.1038/nature13793
19. Pfeffer M., Ziesenitz S. C., Siebert G. Acesulfame K, cyclamate and saccharin inhibit the anaerobic fermentation of glucose by intestinal bacteria. Z. Ernahrungswiss. 1985; 24 (4): 231–5. DOI: 10.1007/BF02023668
20. Suez J., Korem T., Zilberman-Schapira G. et al. Non-caloric artificial sweeteners and the microbiome: findings and challenges. Gut Microbes. 2015; 6: 149–55.
21. Rubenstein L., Robinson J., Seguin R. A. et al. Diet drink consumption and the risk of cardiovascular events: a report from the Women’s Health Initiative. J. Gen. Intern. Med. 2015; 30 (4): 462–8. DOI: 10.1007/s11606–014–3098–0
22. de Koning L., Malik V. S., Kellogg M. D. et al. Sweetened Beverage Consumption, Incident Coronary Heart Disease, and Biomarkers of Risk in Men. Circulation. 2012; 125: 1735–1741. https: doi.org/10.1161/CIRCULATIONAHA.111.067017
23. Duffey K. J., Steffen L. M., Van Horn L. et al. Dietary patterns matter: diet beverages and cardiometabolic risks in the longitudinal Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J. Clin. Nutr. 2012; 95 (4): 909–915. DOI: 10.3945/ajcn.111.026682
24. Gardener H. R.T., Markert M., Wright C. B. et al. Diet soft drink consumption is associated with an increased risk of vascular events in the northern manhattan study. J. Gen. Intern. Med. 2012; 27:1120–1126. DOI: 10.1007/s11606–011–1968–2
25. Swithers S. E. Artificial sweeteners produce the counterintuitive effect of inducing metabolic derangements. Trends Endocrinol Metab. 2013; 24 (9): 431–41. DOI: 10.1016/j.tem.2013.05.005
26. Schiano C., Grimaldi V., Scognamiglio M. et al. Soft drinks and sweeteners intake: Possible contribution to the development of metabolic syndrome and cardiovascular diseases. Beneficial or detrimental action of alternative sweeteners? Food. Res. Int. 2021; 142: 110220. DOI: 10.1016/j.foodres.2021.110220
27. Chazelas E., Debras C., Srour B. et al. Sugary Drinks, Artificially-Sweetened Beverages, and Cardiovascular Disease in the NutriNet-Santé Cohort. JACC Journals. 2020; 76 (18): 2175–2177.
28. Kramers P. G.N. The mutagenicity of saccharine. Mutation research. Reviews I Genetic Toxicology. 1975; 32 (1): 81–92.
29. Assadi-Porter F.M., Maillet E. L., Radek J. T. et al. Key amino acid residues involved in multi-point binding interactions between brazzein, a sweet protein, and the T1R 2-T1R 3 human sweet receptor. Journal of molecular biology. 2010; 398 (4): 584–599.
Review
For citations:
Maev I.V., Zaborovsky A.V., Tsaregorodtsev S.V., Yunina D.V., Kolosov Yu.A., Starovoytova M.Yu., Tararina L.A. The use of sweeteners and sugar substitutes in the food industry. Sweet proteins as a new alternative. Medical alphabet. 2024;(16):58‑64. (In Russ.) https://doi.org/10.33667/2078-5631-2024-16-58-64
Views:
257
Email this article 